Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 17/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8001356 | 0.86 | HPGDS (0.70) | HPGDSMAOB | |
| SCHEMBL13113540 | 0.83 | MGAM (0.56) | HPGDS | |
| SCHEMBL13925715 | 0.83 | HPGDS (0.53) | HPGDS | |
| SCHEMBL10473057 | 0.76 | MGAM (0.62) | HPGDSMAOBCYP2A6 | |
| SCHEMBL17221411 | 0.76 | MAOB (0.53) | HPGDSMAOB | |
| SCHEMBL12488090 | 0.75 | MAOB (0.49) | HPGDSMAOBCYP2A6 | |
| SCHEMBL30494336 | 0.75 | HPGDS (0.66) | HPGDSMAOBCYP2A6 | |
| SCHEMBL13574439 | 0.74 | KMT2A (0.49) | L3MBTL1 | |
| SCHEMBL8001650 | 0.73 | MAOB (0.71) | HPGDSMAOBL3MBTL1 | |
| SCHEMBL5436981 | 0.72 | TDP1 (0.60) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BCOR, BRDT, TPMT | HPGDS 1713/4885MAOB 579/4885L3MBTL1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.